At Batu Biologics we believe the most potent medicines are to be found within the patient’s body, the key is to unleash them. Our products are centered around the idea of creating or breaking immune tolerance. The company is currently in the preclinical stage of drug development for its flagship products: Vallovax™. Batu Biologics has also recently exclusively licensed vaccine adjuvant technology from UC San Diego.
Who We Are
Batu Biologics is a biopharmaceutical company based in San Diego seeking to rapidly translate novel cell and gene therapies for the treatment of cancer. Batu is focused on developing the “ValloVax™” platform, an allogeneic and universal donor cellular vaccine designed to stimulate a targeted immune response against the blood vessels of the tumor for a wide array of cancers.
• Research of cancer immunotherapy
• Preclinical development of ValloVax™
• IP expansion and licensing opportunities
• Contractual Research
• Academic Collaborations
Latest News & Events:
Batu Biologics Introduces ValloVax Immunotherapy
Batu Biologics is a biotechnology-based pharmaceutical company focused on the development and commercialization of novel therapies that target the “Achilles Heel of Cancer”: the tumor blood vessels. Batu’s flagship therapeutic, ValloVax™, is an angiogenesis targeting cancer vaccine in the late stages of preclinical development. Batu Biologics has currently filed an Investigational New Drug Application (IND # 16296) for the initial indication of non-small cell lung cancer (NSCLC), and anticipates clinical approval to begin treating patients in 2017.